pharmachologic effect
Glucocorticosteroid for local use.
Has anti-inflammatory and anti-allergic effects.
Inhibits the release of inflammatory mediators, increases the production of lipomodulin - an inhibitor of phospholipase A, reduces the release of arachidonic acid, and inhibits the synthesis of prostaglandins. Prevents the marginal accumulation of neutrophils, reducing the formation of inflammatory exudate and the production of lymphokines, inhibits the migration of macrophages, which leads to a slowdown in the processes of infiltration and granulation.
Increases the number of active β-adrenergic receptors, neutralizes their desensitization, restores the patient's response to bronchodilators, allowing them to be used less frequently.
Under the influence of beclomethasone, the number of mast cells in the bronchial mucosa decreases, the swelling of the epithelium and the secretion of mucus by the bronchial glands decreases. Causes relaxation of bronchial smooth muscles, reduces their hyperreactivity and improves external respiration function.
Does not have mineralocorticoid activity.
In therapeutic doses it does not cause side effects characteristic of systemic corticosteroids.
The therapeutic effect usually develops after 5-7 days of course use of beclomethasone.
Directions for use and doses
Inhalation.
- Bronchial asthma
Adults and children aged 12 years and older. Beclomethasone aeronate is used regularly (even in the absence of symptoms of the disease), the dose of beclomethasone dipropionate is selected taking into account the severity of bronchial asthma and the clinical effect in each specific case. The daily dose is divided into several doses.
Recommended initial doses of the drug:
mild bronchial asthma - 200–600 mcg/day;
moderate bronchial asthma - 600–1000 mcg/day;
severe bronchial asthma - 1000–2000 mcg/day.
Children aged 4 to 12 years. Up to 400 mcg/day in several doses.
Depending on the patient's individual response, the dose of the drug can be increased until a clinical effect appears or reduced to the minimum effective dose.
When switching to a high dose of inhaled beclomethasone dipropionate in many patients receiving systemic corticosteroids, it is possible to reduce their dose or discontinue them completely.
- COPD
The maximum recommended dose of Beclomethasone-aeronativ for COPD is 2000 mcg/day.
If you accidentally miss an inhalation, the next dose must be taken at the scheduled time in accordance with the treatment regimen.
Administration can be carried out using special dispensers (spacers), which improve the distribution of the drug in the lungs and reduce the risk of side effects.
Beclomethasone-aeronativ aeroz 250 µg/dose 200 doses (Nativa)
Before prescribing inhaled drugs, it is necessary to instruct the patient on the rules for their use, ensuring the most complete delivery of the drug to the desired areas of the lungs. To prevent oral candidiasis, after inhalation you should rinse your mouth and throat with water. To treat candidiasis, topical antifungal drugs can be used while continuing Beclomethasone-aeronativ therapy. If patients take GCS orally, then Beclomethasone-aeronative is prescribed while taking the previous dose of GCS, and the patients should be in a relatively stable condition. After about 1 to 2 weeks, the daily dose of oral corticosteroids begins to be gradually reduced. The dose reduction scheme depends on the duration of previous therapy and the size of the initial dose of GCS. Regular use of inhaled GCS allows in most cases to cancel oral GCS (patients who need to take no more than 15 mg of prednisolone can be completely transferred to inhaled therapy), while in the first months after the transition the patient’s condition should be carefully monitored until his pituitary-adrenal the system will not recover sufficiently to provide an adequate response to stressful situations (such as injury, surgery, or infection). When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema) that were previously suppressed by systemic drugs may occur. Patients with reduced function of the adrenal cortex, transferred to inhalation treatment, should have a supply of GCS and always carry a warning card with them, the LP 002051-150413 of which should indicate that in stressful situations they need additional systemic administration of GCS (after eliminating the stressful situation The dose of GCS can be reduced again). A sudden and progressive worsening of asthma symptoms is a potentially dangerous condition, often life-threatening for patients, and requires an increase in the dose of GCS. An indirect indicator of the ineffectiveness of therapy is the more frequent use of short-acting b2-agonists than before. Beclomethasone aeronative is not intended for the relief of attacks, but for regular daily use. To relieve attacks, short-acting b2-agonists (for example, salbutamol) are used. In case of severe exacerbation of bronchial asthma or insufficient effectiveness of the therapy, the dose of the drug "Beclomethasone-aeronativ" should be increased and, if necessary, a systemic corticosteroid and/or an antibiotic should be prescribed if the infection develops. If paradoxical bronchospasm develops, you should immediately stop using Beclomethasone Aeronative, assess the patient’s condition, conduct an examination and, if necessary, prescribe therapy with other drugs. With long-term use of any inhaled corticosteroids, especially in high doses, systemic effects may be observed (see “Side effects”), but the likelihood of their development is much lower than when taking corticosteroids orally. Therefore, it is especially important that when a therapeutic effect is achieved, the dose of inhaled corticosteroids is reduced to the minimum effective dose that controls the course of the disease. At a dose of 1500 mcg/day, the drug does not cause significant suppression of adrenal function in most patients. Due to possible adrenal insufficiency, special care should be taken and regular monitoring of adrenal function indicators when transferring patients taking oral corticosteroids to treatment with Beclomethasone-Aeronativ. Sharp o. is not recommended. Particular care should be taken when treating patients with active or inactive forms of pulmonary tuberculosis with inhaled corticosteroids. It is necessary to protect the eyes from contact with the drug. By washing after inhalation you can prevent damage to the skin of the eyelids and nose. The can of Beclomethasone Aeronative must not be pierced, disassembled or thrown into a fire, even if it is empty. Like most other inhalation aerosol products, Beclomethasone aerosol may be less effective at low temperatures. When the canister is cooling, it is recommended to remove it from the plastic LP 002051-150413 case and warm it with your hands for several minutes. Peculiarities of the action of the drug when it is discontinued Due to the risk of exacerbation, sudden withdrawal should be avoided. The dose of the drug should be reduced gradually under the supervision of a physician. Effect on the ability to drive vehicles and operate machinery Beclomethasone-aeronativ does not affect the ability to drive vehicles and operate machinery.
special instructions
Beclomethasone is not intended for the relief of acute asthmatic attacks. It should also not be used for severe asthma attacks requiring intensive care. The recommended route of administration for the dosage form used should be strictly followed.
Beclomethasone should be used with extreme caution and under close medical supervision in patients with adrenal insufficiency.
The transfer of patients who constantly take GCS orally to inhaled forms can be done only if their condition is stable.
If there is a possibility of developing paradoxical bronchospasm, bronchodilators (for example, salbutamol) are inhaled 10-15 minutes before the administration of beclomethasone.
With the development of candidiasis of the oral cavity and upper respiratory tract, local antifungal therapy is indicated without stopping treatment with beclomethasone. Infectious and inflammatory diseases of the nasal cavity and paranasal sinuses, if appropriate therapy is prescribed, are not a contraindication for treatment with beclomethasone.
Beclometasone-aeronativ
Before prescribing inhaled drugs, it is necessary to instruct the patient on the rules for their use, ensuring the most complete delivery of the drug to the desired areas of the lungs. To prevent oral candidiasis, after inhalation you should rinse your mouth and throat with water. To treat candidiasis, topical antifungal drugs can be used while simultaneously continuing therapy with Beclomethasone-aeronativ.
If patients take GCS orally, then Beclomethasone-aeronative is prescribed while taking the previous dose of GCS, and the patients should be in a relatively stable condition. After about 1 to 2 weeks, the daily dose of oral corticosteroids begins to be gradually reduced. The dose reduction scheme depends on the duration of previous therapy and the size of the initial dose of GCS. Regular use of inhaled GCS allows in most cases to cancel oral GCS (patients who need to take no more than 15 mg of prednisolone can be completely transferred to inhaled therapy), while in the first months after the transition the patient’s condition should be carefully monitored until his pituitary-adrenal system will recover sufficiently to provide an adequate response to stressful situations (for example, injury, surgery, or infection).
When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema) that were previously suppressed by systemic drugs may occur.
Patients with reduced function of the adrenal cortex who are transferred to inhalation treatment should have a supply of GCS and always carry a warning card with them, which should indicate that in stressful situations they need additional systemic administration of GCS (after eliminating the stressful situation, the dose of GCS can be repeated reduce). A sudden and progressive worsening of asthma symptoms is a potentially dangerous condition, often life-threatening for patients, and requires an increase in the dose of GCS. An indirect indicator of the ineffectiveness of therapy is the more frequent use of short-acting beta2-agonists than before.
Beclomethasone aeronative is not intended for the relief of attacks, but for regular daily use. To relieve attacks, short-acting beta2-agonists (for example, salbutamol) are used. In case of severe exacerbation of bronchial asthma or insufficient effectiveness of the therapy, the dose of the drug "Beclomethasone-aeronativ" should be increased and, if necessary, a systemic corticosteroid and/or an antibiotic should be prescribed if the infection develops.
If paradoxical bronchospasm develops, you should immediately stop using Beclomethasone Aeronative, assess the patient’s condition, conduct an examination and, if necessary, prescribe therapy with other drugs. With long-term use of any inhaled corticosteroids, especially in high doses, systemic effects may be observed (see “Side effects”), but the likelihood of their development is much lower than when taking corticosteroids orally. Therefore, it is especially important that when a therapeutic effect is achieved, the dose of inhaled corticosteroids is reduced to the minimum effective dose that controls the course of the disease. At a dose of 1500 mcg/day, the drug does not cause significant suppression of adrenal function in most patients. Due to possible adrenal insufficiency, special care should be taken and regular monitoring of adrenal function indicators when transferring patients taking oral corticosteroids to treatment with Beclomethasone-Aeronativ.
Sharp o. is not recommended.
Particular care should be taken when treating patients with active or inactive forms of pulmonary tuberculosis with inhaled corticosteroids.
It is necessary to protect the eyes from contact with the drug. By washing after inhalation you can prevent damage to the skin of the eyelids and nose.
The Beclomethasone Aeronative canister must not be pierced, disassembled or thrown into fire, even if it is empty. Like most other inhalation aerosol products, Beclomethasone aerosol may be less effective at low temperatures. When the canister cools down, it is recommended to remove it from the plastic case and warm it with your hands for a few minutes.
Features of the action of the drug upon its withdrawal
Due to the risk of exacerbation, sudden o.g. should be avoided. The dose of the drug should be reduced gradually under the supervision of a physician.
